Table 1. . Patient, disease and treatment characteristics for the study participants.
| Patients and tumor characteristics n = 36 (all subjects) | n (%) |
|---|---|
| Age (years): – Median (range) |
60 (40–82) |
| Sex: –Males –Females |
33 (92) 3 (8) |
| Site: –Oropharynx –Larynx –Hypopharynx –Left parotid ––Nasopharynx –Carcinoma unknown primary |
26 (72) 4 (11) 2 (6) 1 (3) 1 (3) 2 (5) |
| Human papillomavirus: –p16+ –p16- –Not specified/–unclear |
24 (67) 1 (3) 11 (30) |
| Stage | |
| Primary tumor (T): –T0 –T1 –T2 –T3 –T4 |
2 (5) 9 (25) 15 (42) 5 (14) 5 (14) |
| Node involvement (N): –N1 –N2 –N3 |
21 (58) 10 (28) 5 (14) |
| Systemic therapy | |
| Chemotherapy: –Cisplatin (high and low dose) –Carboplatin –Carboplatin + etoposide –Cisplatin + carboplatin |
25 (69) 1 (3) 2 (5) 2 (5) |
| EGFR inhibitor: –Cetuximab |
1 (3) |
| None | 5 (14) |
| Response at 3 months | |
| Treatment response classification: –CR –PR |
14 (39) 22 (61) |
CR: Complete responders; EBV+: Epstein–Barr virus-positive carcinoma; N: Nodal staging (AJCC 8th edition); p16+: Human papillomavirus-positive tumor; PR: Partial responders; T: Primary tumor staging (American Joint Committee on Cancer [AJCC] 8th edition).